Articles From: Imprimis Pharmaceuticals Reports on Positive Clinical Findings Presented at the American Academy of Ophthalmology (AAO) Annual Meeting to Positive Top-Line Results Achieved From Two Phase 1 Clinical Trials of BACE Inhibitor BI1181181/VTP-37948 in Alzheimer's Disease


Dropless cataract surgery created a "buzz" and was a "hot topic" at this year's AAO meeting SAN DIEGO , Oct.
Sign-up for Imprimis Pharmaceuticals Reports on Positive Clinical Findings Presented at the American Academy of Ophthalmology (AAO) Annual Meeting investment picks
--Premier Oilfield Services Company Partners with Apollo to Support Continued Growth- HOUSTON , Oct.
Sign-up for Express Energy Services Agrees To Be Acquired By Apollo Funds investment picks
Qlik® (NASDAQ: QLIK), a leader in data discovery, today announced that AmerisourceBergen, one of the largest global pharmaceutical sourcing and distribution services companies, has signed an enterprise deal to significantly extend its use of Qlik products, deploying both QlikView® and Qlik® Sense widely across the enterprise.
Sign-up for AmerisourceBergen Selects Qlik as Global Standard for Analytics investment picks
JMP Group Inc. (NYSE: JMP ), an investment banking and alternative asset management firm, reported financial results today for the quarter and nine months ended September 30, 2014.
Sign-up for JMP Group Reports Third Quarter 2014 Financial Results investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted its final opinion on Iclusig ® (ponatinib) following the recommendations made by the Pharmacovigilance Risk Assessment Committee (PRAC) earlier this month.
Sign-up for ARIAD Announces Adoption of Final Opinion for Iclusig by Committee for Medicinal Products for Human Use in Europe investment picks
Nexstar Broadcasting Group, Inc. (Nasdaq: NXST) announced today that its Board of Directors declared a quarterly cash dividend of $0.15 per share of its Class A common stock.
Sign-up for Nexstar Broadcasting Group Declares Quarterly Cash Dividend of $0.15 Per Share investment picks
Moody’s Corporation (NYSE:MCO) today announced results for the third quarter 2014.
Sign-up for Moody's Corporation Reports Results for Third Quarter 2014 investment picks
NGL Energy Partners LP (NYSE: NGL) announced today that the Board of Directors of its general partner declared a quarterly distribution of $0.60875 per unit ($2.435 on an annualized basis) for the quarter ended September 30, 2014.
Sign-up for NGL Energy Partners Announces Increased Quarterly Cash Distribution investment picks
The Dixie Group, Inc. (NASDAQ: DXYN) today announced that its Board of Directors appointed William F.
Sign-up for The Dixie Group Appoints William F. Blue, Jr. To the Board investment picks
ImmunoGen, Inc .
Sign-up for ImmunoGen, Inc. Reports First Quarter Fiscal Year 2015 Financial Results investment picks
Conference Call Scheduled for Monday, November 10 LEHI, Utah , Oct.
Sign-up for Vivint Solar to Report Third Quarter 2014 Financial Results investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0974650001&sourceType=1 http://media3.marketwire.com/logos/20140319-delphi.jpg CALGARY, ALBERTA --
Sign-up for Delphi Energy Provides Operations Update investment picks
SAN JOSE, Calif., Oct.
Sign-up for Heritage Commerce Corp Declares Quarterly Cash Dividend of $0.05 Per Share investment picks
CHARLOTTE , Oct.
Sign-up for Tree.com, Inc. to Report Third Quarter 2014 Earnings on November 6, 2014 investment picks
MILLERSBURG, Pa., Oct.
Sign-up for Mid Penn Bancorp, Inc. Reports Third Quarter Earnings and Declares Dividend investment picks
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that its global Phase 2 study of lucitanib in patients with FGFR1-amplified squamous non-small cell lung cancer (NSCLC) has commenced and the first patient has been dosed at a U.S. study site.
Sign-up for Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in Squamous Non-small Cell Lung Cancer investment picks
Pfizer shares (PFE) rose 1.4% in after-hours trade Thusday after the blue-chip drug maker said it has authorized a new $11 billion share buyback program, to be "utilized over time." That is in addition to the $1.3 billion left in its previous repurchase program.
Sign-up for Pfizer shares rise after new $11 billion share buyback program investment picks
http://media.marketwire.com/attachments/201005/596355_LogoHorzLG.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1153755&ProfileId=051205&sourceType=1 BEAVERTON, OR --
Sign-up for Cascade Microtech's MeasureOne(TM) Best-of-Breed Solutions Program Joined by Keysight Technologies investment picks
ATLANTA , Oct.
Sign-up for Alimera Sciences to Release Third Quarter 2014 Results investment picks
TULSA, Okla., Oct.
Sign-up for Rose Rock Midstream, L.P. Increases Distributions on Limited Partner Units investment picks
Net Income Grows 8 Percent From a Year Ago LOS ANGELES, Oct.
Sign-up for City National Corporation Reports Record Net Income of $68.7 Million in the Third Quarter of 2014 investment picks
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers will present seven posters detailing findings from clinical studies of Soliris ® (eculizumab) in patients with atypical hemolytic uremic syndrome (aHUS) as well as from the Global aHUS Registry at the annual meeting of the American Society of Nephrology (ASN), being held November 11-16, 2014, in Philadelphia.
Sign-up for Researchers to Present Data on Soliris® (eculizumab) as a Treatment for Patients with aHUS at ASN 2014 Annual Meeting investment picks
BI1181181/VTP-37948 Demonstrated Greater Than 80% Reduction of an Alzheimer's Disease Biomarker, the Cerebral Spinal Fluid Amyloid Beta Levels BI1181181/VTP-37948 Was Safe and Generally Well-Tolerated With a Profile Supporting Once-Daily Dosing FORT WASHINGTON, Pa., Oct.
Sign-up for Positive Top-Line Results Achieved From Two Phase 1 Clinical Trials of BACE Inhibitor BI1181181/VTP-37948 in Alzheimer's Disease investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Imprimis Pharmaceuticals Reports on Positive Clinical Findings Presented at the American Academy of Ophthalmology (AAO) Annual Meeting to Positive Top-Line Results Achieved From Two Phase 1 Clinical Trials of BACE Inhibitor BI1181181/VTP-37948 in Alzheimer's Disease
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent